

U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Phosphorus P 32. [Updated 2018 Dec 3]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Phosphorus P 32

Revised: December 3, 2018.

CASRN: 14596-37-3



Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of phosphorus P 32 as a therapeutic agent. No information is available on the use of phosphorus P 32 during breastfeeding. Use of phosphate P 32 as a skin patch to treat skin cancers poses no risk to breastfed infants after removal of the patch from the mother's skin

Drug Levels

P 32 is a pure beta-emitting radionuclide with a physical half-life of 14.3 days. The mean beta particle energy is 0.695 MeV.[1]

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Tennvall J, Brans B. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. Eur J Nucl Med Mol Imaging. 2007;34:1324-7. PubMed PMID: 17396258.

Substance Identification

Substance Name

Phosphorus P 32

CAS Registry Number

14596-37-3

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Phosphorus Radioisotopes